clinical trial · NCT07596784
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG)
Alexion Pharmaceuticals, Inc.·phase3·recruiting·n = 20
Generalized Myasthenia GravisgMGRavulizumab
brief summary
The primary purpose of this study is to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of ravulizumab in Chinese adult participants with Acetylcholine receptor (AChR) + Generalized Myasthenia Gravis (gMG).
started
Jul 27, 2026
primary completion
Aug 24, 2027
completion
Aug 24, 2027
last updated
Oct 21, 2026
official title
An Open-label, Single-arm, Multi-center, Interventional Study to Evaluate the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Ravulizumab in Chinese Adult Patients With Generalized Myasthenia Gravis (gMG)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol